MA54412A - Traitement d'excès de graisse hépatique et/ou viscérale - Google Patents

Traitement d'excès de graisse hépatique et/ou viscérale

Info

Publication number
MA54412A
MA54412A MA054412A MA54412A MA54412A MA 54412 A MA54412 A MA 54412A MA 054412 A MA054412 A MA 054412A MA 54412 A MA54412 A MA 54412A MA 54412 A MA54412 A MA 54412A
Authority
MA
Morocco
Prior art keywords
treatment
visceral fat
excess hepatic
hepatic
excess
Prior art date
Application number
MA054412A
Other languages
English (en)
Inventor
Zegher Francis De
Lourdes Ibañez
Original Assignee
Sant Joan De Deu Hospital
Katholieke Univ Leuven Ku Leuven Research & Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sant Joan De Deu Hospital, Katholieke Univ Leuven Ku Leuven Research & Development filed Critical Sant Joan De Deu Hospital
Publication of MA54412A publication Critical patent/MA54412A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054412A 2015-10-27 2016-10-27 Traitement d'excès de graisse hépatique et/ou viscérale MA54412A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1518979.8A GB201518979D0 (en) 2015-10-27 2015-10-27 Treatment of hepatic steatosis related oligo-ovulation

Publications (1)

Publication Number Publication Date
MA54412A true MA54412A (fr) 2021-11-10

Family

ID=55130283

Family Applications (2)

Application Number Title Priority Date Filing Date
MA054412A MA54412A (fr) 2015-10-27 2016-10-27 Traitement d'excès de graisse hépatique et/ou viscérale
MA43106A MA43106B1 (fr) 2015-10-27 2016-10-27 Traitement de l'oligo-ovulation associée à la stéatose hepatique

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA43106A MA43106B1 (fr) 2015-10-27 2016-10-27 Traitement de l'oligo-ovulation associée à la stéatose hepatique

Country Status (24)

Country Link
US (2) US20190060328A1 (fr)
EP (2) EP3368044B1 (fr)
JP (2) JP6999903B2 (fr)
KR (1) KR102608158B1 (fr)
CN (2) CN117379440A (fr)
AR (1) AR106505A1 (fr)
AU (1) AU2016344737C1 (fr)
BR (1) BR112018008496A2 (fr)
CA (1) CA3003076C (fr)
DK (1) DK3368044T3 (fr)
ES (1) ES2883282T3 (fr)
GB (1) GB201518979D0 (fr)
HU (1) HUE055778T2 (fr)
IL (1) IL258876B (fr)
LT (1) LT3368044T (fr)
MA (2) MA54412A (fr)
MX (2) MX384040B (fr)
PL (1) PL3368044T3 (fr)
RS (1) RS62764B1 (fr)
RU (1) RU2745606C2 (fr)
SI (1) SI3368044T1 (fr)
TW (1) TWI791420B (fr)
UY (1) UY36967A (fr)
WO (1) WO2017072243A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020012336A2 (pt) 2017-12-19 2021-03-30 Akouos, Inc. Administração de anticorpos terapêuticos mediada por aav para o ouvido interno
CA3107945A1 (fr) * 2018-08-02 2020-02-06 Hospital Sant Joan De Deu Formulation a liberation immediate d'une triple combinaison d'ingredients pharmaceutiques actifs utile dans le traitement du syndrome des ovaires polykystiques
EP3842803A1 (fr) * 2019-12-23 2021-06-30 Katholieke Universiteit Leuven Cxcl14 dans le syndrome des ovaires polykystiques
IL298128A (en) 2020-05-13 2023-01-01 Akouos Inc Compositions and methods for treating slc26a4-associated hearing loss
AU2021391433A1 (en) 2020-12-01 2023-06-22 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
JP2024500786A (ja) 2020-12-29 2024-01-10 アコーオス インコーポレイテッド Ｃｌｒｎ１関連難聴及び／または視力低下を治療するための組成物及び方法
CA3243517A1 (fr) 2022-02-02 2023-08-10 Akouos, Inc. Constructions d'anticorps anti-vegf et méthodes connexes pour le traitement de symptômes associés au neurinome de l'acoustique

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
AU2001239826B2 (en) * 2000-02-23 2006-06-15 Orentreich Foundation For The Advancement Of Science, Inc. Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
GB0106565D0 (en) * 2001-03-16 2001-05-09 Leuven K U Res & Dev Growth hormone treatment
GB0108863D0 (en) * 2001-04-10 2001-05-30 Leuven K U Res & Dev Combinational therapy
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2004052390A1 (fr) * 2002-12-11 2004-06-24 Amylin Pharmaceuticals, Inc. Methodes et compositions de traitement du syndrome stein-leventhal
GB0702537D0 (en) 2007-02-12 2007-03-21 Leuven K U Res & Dev Treatment for excessive adiposity
US10474539B1 (en) * 2015-12-18 2019-11-12 EMC IP Holding Company LLC Browsing federated backups
CA3107945A1 (fr) * 2018-08-02 2020-02-06 Hospital Sant Joan De Deu Formulation a liberation immediate d'une triple combinaison d'ingredients pharmaceutiques actifs utile dans le traitement du syndrome des ovaires polykystiques

Also Published As

Publication number Publication date
RU2745606C2 (ru) 2021-03-29
WO2017072243A8 (fr) 2018-03-22
RU2018119146A (ru) 2019-11-28
WO2017072243A9 (fr) 2018-07-26
MX2021007976A (es) 2021-08-16
IL258876B (en) 2022-03-01
RS62764B1 (sr) 2022-01-31
EP3892281A3 (fr) 2021-11-10
BR112018008496A2 (pt) 2018-10-23
UY36967A (es) 2017-05-31
JP6999903B2 (ja) 2022-02-04
EP3892281A2 (fr) 2021-10-13
US20190060328A1 (en) 2019-02-28
MA43106A (fr) 2021-05-05
TWI791420B (zh) 2023-02-11
JP2019501113A (ja) 2019-01-17
US20240000804A1 (en) 2024-01-04
IL258876A (en) 2018-06-28
HUE055778T2 (hu) 2021-12-28
MA43106B1 (fr) 2021-09-30
ES2883282T3 (es) 2021-12-07
KR102608158B1 (ko) 2023-11-29
EP3368044B1 (fr) 2021-06-09
EP3368044A1 (fr) 2018-09-05
AU2016344737C1 (en) 2021-10-07
CN108778285A (zh) 2018-11-09
PL3368044T3 (pl) 2021-12-20
AU2016344737A1 (en) 2018-05-17
RU2018119146A3 (fr) 2020-02-25
JP2022009374A (ja) 2022-01-14
TW201720432A (zh) 2017-06-16
LT3368044T (lt) 2021-10-25
AU2016344737B2 (en) 2021-07-08
MX384040B (es) 2025-03-14
GB201518979D0 (en) 2015-12-09
SI3368044T1 (sl) 2022-05-31
DK3368044T3 (da) 2021-09-13
MX2018005252A (es) 2018-09-18
CA3003076C (fr) 2023-12-05
AU2016344737A9 (en) 2018-08-09
AR106505A1 (es) 2018-01-24
CN117379440A (zh) 2024-01-12
WO2017072243A1 (fr) 2017-05-04
KR20180098234A (ko) 2018-09-03
CA3003076A1 (fr) 2017-05-04

Similar Documents

Publication Publication Date Title
EP3370721A4 (fr) Traitement de l'ostéoarthrite
EP3370748A4 (fr) Microbiote thérapeutique pour le traitement et/ou la prévention de l'allergie alimentaire
MA54412A (fr) Traitement d'excès de graisse hépatique et/ou viscérale
MA45192A (fr) Traitement d'association
EP3607072A4 (fr) Compositions et méthodes de traitement de la phénylcétonurie
EP3370617A4 (fr) Système non invasif d'imagerie et de traitement des arythmies cardiaques
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP3397149A4 (fr) Cartographie et traitement de tissu
PL3411052T3 (pl) Zastosowanie skupisk drobnoustrojów dla zdrowia ludzi i zwierząt
EP3364869A4 (fr) Traitement contrôlé et précis de tissus cardiaques
EP3452166A4 (fr) Stimulation intranasale pour le traitement de la maladie de la glande de meibomius et de la blépharite
MA42450A (fr) Méthodes de traitement de la stéatose hépatique non alcoolique et/ou de la lipodystrophie
EP3359085A4 (fr) Traitement contrôlé et précis de tissus cardiaques
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
EP3713583A4 (fr) Méthodes et compositions pour le traitement de la peau
EP3454793A4 (fr) Bobines de traitement d'anévrisme
HUE059387T2 (hu) Parkinson-kór kezelése
EP3376977A4 (fr) Récupération et traitement d'embryons humains formésin vivo
EP3347032A4 (fr) Traitement de l'ascite
EP3344258A4 (fr) Traitement de maladies auto-immunes et de maladies auto-inflammatoires
EP3365014A4 (fr) Méthodes et compositions pour le traitement de la mastocytose systémique
MA41120A (fr) Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
EP3395341A4 (fr) Composition pour le traitement de maladies neuromotrices et son utilisation
EP3458062A4 (fr) Traitement de la douleur